Kamada Ltd stock (IL0010952647): biotech shares in focus after recent quarterly update

Kamada Ltd, the Israeli plasma-derived protein and specialty plasma company, has been back in the news after its latest quarterly earnings release. The biotech’s U.S.-listed shares attract attention from investors watching rare-disease and plasma markets.

Kamada Ltd has moved back into the spotlight after reporting its most recent quarterly results and business update, giving investors fresh insight into the plasma-derived therapies specialist and its U.S.-listed stock. The company published first-quarter 2025 financial figures on May 13, 2025, including revenue trends in its plasma-derived immunoglobulin and specialty plasma segments, according to Kamada press release as of 05/13/2025. The update also included commentary on demand trends and the company’s strategic priorities, which remain closely followed by investors active in biotech and rare-disease stocks.

On the market side, Kamada’s shares, which trade on Nasdaq under the ticker KMDA, continue to show sensitivity to earnings headlines, pipeline progress and broader sentiment in the biotech and plasma-derived products space. The stock traded around the mid-single-digit dollar range in recent months, with moves often influenced by quarterly numbers and guidance commentary, based on price data from Nasdaq as referenced by financial portals in early 2025, according to Nasdaq market data as of 03/31/2025.

As of: 17.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Kamada Ltd
• Sector/industry: Biopharmaceuticals, plasma-derived therapies
• Headquarters/country: Israel
• Core markets: United States, Europe and other international plasma and rare-disease markets
• Key revenue drivers: Plasma-derived protein therapeutics, specialty plasma products and contract manufacturing
• Home exchange/listing venue: Nasdaq (ticker: KMDA)
• Trading currency: USD on Nasdaq, ILS on the Tel Aviv Stock Exchange

Kamada Ltd: core business model

Kamada focuses on developing, manufacturing and commercializing plasma-derived protein therapeutics and specialty plasma products. The company has built its business around a portfolio of products addressing rare and serious conditions, where patients often have limited treatment options and where payers may accept premium pricing for effective therapies, according to company descriptions in its annual filing published on March 21, 2024, for the 2023 financial year, as noted by SEC Form 20-F as of 03/21/2024.

At the heart of Kamada’s model are plasma-derived therapies, which are complex biological products manufactured from human plasma and require specialized collection, fractionation and purification processes. The company also operates specialty plasma collection activities and engages in contract manufacturing for third parties, leveraging its manufacturing facilities, quality systems and regulatory approvals to generate additional revenue streams, based on management commentary in its full-year 2023 report released in March 2024, according to Kamada press release as of 03/21/2024.

The company’s exposure to the United States is particularly important, as the U.S. market is one of the world’s largest for plasma-derived immunoglobulins and rare-disease treatments. U.S. demand patterns, reimbursement frameworks and regulatory decisions from the Food and Drug Administration can therefore have a significant influence on Kamada’s long-term growth profile and on how investors assess the risk-reward balance of the stock.

Main revenue and product drivers for Kamada Ltd

Kamada’s revenue base is primarily derived from its plasma-derived immunoglobulin and specialty plasma product portfolio, complemented by contract manufacturing services. In the first quarter of 2025, management highlighted revenue performance across its immunoglobulin and specialty plasma franchises, noting the contribution from its hyperimmune and anti-rabies immunoglobulin offerings, according to the company’s Q1 2025 statement dated May 13, 2025, as summarized by Kamada press release as of 05/13/2025.

Beyond individual products, Kamada’s revenue trajectory depends on several structural factors: the underlying prevalence of rare diseases addressed by its therapies, physician adoption and treatment guidelines, and its ability to secure supply agreements with distributors and health systems. Additionally, the company’s contract manufacturing activities utilize its plasma-processing expertise to generate relatively stable revenue streams, which can help offset some of the volatility associated with product sales that depend on tender cycles or competitive dynamics in specific countries.

In previous periods, Kamada reported that a meaningful share of its sales came from international tenders and agreements for specific hyperimmune products, which can lead to quarter-to-quarter fluctuations in reported revenue depending on the timing of orders and shipments. This pattern was highlighted in financial commentary around the 2023 and early 2024 results, where management pointed to the impact of the timing of large orders on quarterly comparisons, according to Kamada press release as of 05/23/2024.

Another important driver is pricing. In the plasma-derived therapies market, pricing dynamics can be influenced by supply constraints, regulatory changes and competition. Kamada has previously highlighted the benefit of favorable pricing environments for certain immunoglobulin and hyperimmune products, which supported revenue growth in selected periods, as indicated in its full-year 2023 commentary published in March 2024, according to Kamada press release as of 03/21/2024.

On the cost side, margins are shaped by plasma collection expenses, manufacturing utilization, and the complexity of regulatory compliance across different jurisdictions. When production volumes increase and facilities run at higher utilization, fixed costs can be spread across a larger output base, potentially supporting margin expansion. Conversely, lower volumes or shifts in product mix toward lower-margin contracts can weigh on profitability.

Conclusion

Kamada Ltd remains a focused player in the niche market for plasma-derived protein therapeutics and specialty plasma products, with a business model tied closely to rare-disease and immunoglobulin demand. The company’s latest quarterly results from May 2025 provide investors with an updated snapshot of revenue trends, product mix and margin development. For U.S. investors, the Nasdaq-listed shares offer exposure to both the therapeutic potential and the operational complexity of plasma-derived products, including sensitivities to tender cycles, regulatory environments and manufacturing efficiency. As with many biotech and specialty pharma stocks, the balance between growth opportunities and execution risks is central to how the market prices Kamada over time.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.